---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-001058"
form_type: "8-K"
ticker: "LFMD"
cik: "0000948320"
company_name: "LifeMD, Inc."
filed_at: "2022-01-12T23:59:59+00:00"
generated_at: "2026-06-27T18:48:53.383672+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# LifeMD acquires allergy telehealth platform Cleared; total consideration up to $76.7M

## Summary
- Upfront $460k cash + $3.46M milestone payments + up to $72.8M earn-out based on $150M revenue.
- Acquisition expected to close in Q1 2022; Cleared provides allergy/asthma telehealth in all 50 states.
- Deal expected to be accretive to LifeMD's Adjusted EBITDA in 2022 and significantly accretive thereafter.
- LifeMD also purchasing a $507k convertible note from a strategic pharma investor alongside the acquisition.

## SEC filing metadata
- accession: 0001493152-22-001058
- form_type: 8-K
- ticker: LFMD
- cik: 0000948320
- company_name: LifeMD, Inc.
- filed_at: 2022-01-12T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/948320/000149315222001058/0001493152-22-001058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/948320/000149315222001058/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-001058
- JSON: https://secwatch.observer/filing/0001493152-22-001058.json
- Plain text: https://secwatch.observer/filing/0001493152-22-001058.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.